The Technical AnalystExchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Simulations Plus Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.46% $44.70
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 893.33 mill |
| EPS: | 0.520 |
| P/E: | 85.96 |
| Earnings Date: | Jul 04, 2024 |
| SharesOutstanding: | 19.98 mill |
| Avg Daily Volume: | 0.106 mill |
| RATING 2024-04-17 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 85.96 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 85.96 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$34.69 (-22.39%) $-10.01 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 43.24 - 46.16 ( +/- 3.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Woltosz Walter S | Sell | 19 410 | Common Stock |
| 2024-04-01 | Woltosz Walter S | Sell | 590 | Common Stock |
| 2024-03-28 | Szot Daniel | Buy | 30 000 | Stock Options (Right to Buy) |
| 2024-03-01 | Woltosz Walter S | Sell | 17 600 | Common Stock |
| 2024-03-01 | Woltosz Walter S | Sell | 2 400 | Common Stock |
| INSIDER POWER |
|---|
| -41.38 |
| Last 97 transactions |
| Buy: 243 785 | Sell: 655 613 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $44.70 (-1.46% ) |
| Volume | 0.0796 mill |
| Avg. Vol. | 0.106 mill |
| % of Avg. Vol | 75.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SLP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $40.39 | N/A | Active |
|---|
SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Latest Press Releases
Latest News
